All Stories

  1. Adolescent health across Asia Pacific, 2000–23: a systematic analysis for the Global Burden of Disease Study 2023
  2. Ferroptosis-Targeted Strategies to Counter Hypoxia- and Acidosis-Associated Immunosuppression in the Tumor Microenvironment
  3. Global, Regional, and National Burden of Heart Failure, 1990-2023
  4. KLF transcription factors in metabolic kidney disease: from podocyte protection to tubulointerstitial fibrosis
  5. BDNF-related brain–liver communication in metabolic syndrome: implications for anxiety and depression
  6. Homeobox genes in endocrine tumorigenesis: mechanisms, tumor microenvironment interaction, and therapeutic potential
  7. Programmed cell death in kidney disease: integrated crosstalk among ferroptosis, pyroptosis, apoptosis, and cuproptosis
  8. Akkermansia-associated microbial modules and functional metabolic axes link gut microbiome to adiposity across humans and mice
  9. Ischemic Heart Disease in G20 Countries: Forecasted Burden and Regional Disparities Based on GBD 2023 Estimates
  10. The Mediating Role of Atherogenic Index of Plasma in the Association Between Dietary Inflammatory Index and Metabolic Syndrome: Evidence from NHANES and CHARLS
  11. Rising Global Burden and Sex Disparities in Nonmelanoma Skin Cancer: 1990-2021 Trends With Projections to 2036
  12. Inflammatory and hormonal crosstalk linking rheumatic fever to chronic valvular heart disease
  13. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
  14. Regulated cell death pathways in endocrine tumor plasticity: A narrative review
  15. Immunometabolic Remodeling in Ischemic and Non-Ischemic Heart Failure
  16. Regional Inequities in Metabolic Dysfunction–associated Steatotic Liver Disease Burden and Care Quality in High-burden Settings: Implications for Health Systems
  17. Editorial: Association of diabetes mellitus with cognitive impairment and neurological disorders, volume II
  18. Targeting Ferroptosis and Pyroptosis in Cardiovascular Diseases: Mechanisms and Therapeutic Implication
  19. From AKI to CKD mechanisms of maladaptive repair and disease progression
  20. Trends and determinants of childhood anxiety disorders burden in Asia, 1990–2023
  21. Natural Monomer Compounds in Neurodegenerative Diseases: Targeting Ferroptosis and Neuroinflammation
  22. Global, Regional and National Burden of Pulmonary Arterial Hypertension in Young and Middle-Aged Adults, 1990–2021, with Projections to 2045
  23. RNA methylation in cardiovascular remodeling: Molecular mechanisms, biomarkers, and therapeutic strategies
  24. Regional disparities and metabolic determinants of type 2 diabetes in women aged 55 and older
  25. Exploring the Therapeutic Role of Pregnane X Receptor Activation in Acute Kidney Injury: Mechanisms and Clinical Implications
  26. Temporal patterns and predictive factors of depressive disorders among adolescents and young people in Asia
  27. miR‐210 in Ischemic Cardiovascular Disease: Functions, Mechanisms, and Therapeutic Potential
  28. The gut-brain axis in diabetic neuropathy, cognitive impairment, and emotional disorders
  29. Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions
  30. STAT Signaling in Metabolic Disorders: From Molecular Mechanisms to Therapeutic Implications
  31. Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023
  32. Multifaceted elucidation of aminoguanidine in protecting against diabetes-induced vascular endothelial injury
  33. Global Trends and Projections in Chronic Kidney Disease Burden from Diabetes, Hypertension, and Glomerulonephritis: A Population-Based Study
  34. Microbiota-Targeted Modulation of the Gut–Kidney Axis in Diabetic Kidney Disease: Therapeutic Advances and Future Perspectives
  35. Temporal Patterns and Predictive Factors of Childhood Depressive Disorders Across Asia
  36. Diverging regional inequalities in childhood diabetes, 1990–2023: a GBD 2023-based analysis
  37. Exploring Causal Links Between 91 Circulating Inflammatory Proteins and Hashimoto’s Thyroiditis: A Bidirectional Mendelian Randomization Study
  38. The effects of selenium supplementation on cardiovascular risk factors in patients with metabolic diseases ‒ A systematic review and meta-analysis of randomized controlled trials
  39. Sterol Regulatory Element-Binding Proteins and Metabolic Diseases: Mechanisms, Implications, and Therapeutic Strategies
  40. Association between cardiometabolic index and thyroid function: insights from NHANES
  41. The Role of Lactate Metabolism in Tumors
  42. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  43. Autophagy–senescence interplay in kidney disease: mechanistic insights and therapeutic potential
  44. Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
  45. Epidemiology of metabolic dysfunction-associated steatotic liver disease -related liver diseases: 1990–2021 and projections to 2045
  46. Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990–2021: a systematic analysis of the global burden of disease study
  47. Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential
  48. Ribosome collisions and ZAKα activation: explores the therapeutic potential of metabolic diseases
  49. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  50. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  51. METTL3-mediated m6A methylation: implications for diabetes pathogenesis and therapeutic potential
  52. The role and therapeutic potential of exosome-mediated microRNAs regulatory networks in diabetic kidney disease
  53. Editorial: Novel approaches to diet, exercise, and drugs in childhood obesity and metabolic diseases
  54. Efficacy and safety benefits of HR17031 , a fixed‐ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with ty...
  55. Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
  56. Multimodal Neuroimaging of Brain Structure, Metabolism, and Function in Obesity: Current Landscape and Future Perspectives
  57. Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
  58. Global epidemiology and burden of type 2 diabetes in adults aged 55 and older: insights from 1990 to 2021
  59. Aging-Related Obesity: Unveiling Mitochondrial and Metabolic Dysfunction
  60. The global, regional, and national burden and attributable risk factors of Alzheimer's disease and other dementias, 1990-2021: A systematic analysis for the Global Burden of Disease Study
  61. Global epidemiology of type 1 diabetes in youth: 1990–2021 and projections to 2045
  62. Therapeutic Potential of Ginsenosides in the Treatment of Endocrine Diseases: Roles and Mechanisms
  63. Epigenetic regulation of nuclear receptors: Implications for endocrine-related diseases and therapeutic strategies
  64. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045
  65. Nutritional Influences on Brown and Beige Adipocyte: Unraveling the Molecular Mechanisms and Metabolic Implications
  66. Associations between visceral adipose index, lipid accumulation products, and thyroid function parameters in U.S. Adults: analysis of NHANES data
  67. Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies
  68. Glycerophospholipid and Sphingosine- 1-phosphate Metabolism in Cardiovascular Disease: Mechanisms and Therapeutic Potential
  69. KRAS Mutations in Cancer
  70. Updated Insights on Childhood Diabetes Epidemiology 2019-2021 and Projections to 2045
  71. Revolutionizing public health through digital health technology
  72. Exploring heparin’s protective mechanism against AGEs induced endothelial injury
  73. Editorial: Metabolic diseases and healthy aging: prevention and public health policy based on risk factors
  74. The influence of perceived formative assessment on the learning autonomy of medical students: the chain mediating role of psychological empowerment and positive academic emotions
  75. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation
  76. The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities
  77. Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice
  78. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
  79. Metagenomic and metabolomic analysis showing the adverse risk–benefit trade-off of the ketogenic diet
  80. Exploring the multi-targeting phytoestrogen potential of Calycosin for cancer treatment: A review
  81. The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy
  82. Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  83. Epidemiology of 369 diseases and injuries attributable to 84 risk factors: 1990–2019 with 2040 projection
  84. Environmental toxicology of bisphenol A: Mechanistic insights and clinical implications on the neuroendocrine system
  85. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3‐mediated Wnt/β‑catenin signaling pathway
  86. Editorial: Potential pathophysiological mechanisms underlying the comorbidity of depression and macrovascular diseases
  87. Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions
  88. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
  89. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health
  90. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
  91. Changing trends of the diseases burden attributable to high BMI in Asia from 1990 to 2019: results from the global burden of disease study 2019
  92. Secreted frizzled-related protein 5: A promising therapeutic target for metabolic diseases via regulation of Wnt signaling
  93. Secreted frizzled-related proteins: A promising therapeutic target for cancer therapy through Wnt signaling inhibition
  94. Role of dysfunctional peri-organ adipose tissue in metabolic disease
  95. Editorial: Incretin agonists in the treatment of obesity
  96. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease
  97. Global, Regional, and National Epidemiology of Diabetes in Children From 1990 to 2019
  98. Astrocytes in Post-Stroke Depression: Roles in Inflammation, Neurotransmission, and Neurotrophin Signaling
  99. Editorial: Clinical and genetic determinants of diabetes and complications
  100. Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules
  101. Editorial: The impact of adipose tissue dysfunction on cardiovascular and renal disease, Volume II
  102. Global, Regional, and National Burden of Pancreatic Cancer, 1990–2019: Results from the Global Burden of Disease Study 2019
  103. Editorial: Aging and chronic disease: public health challenge and education reform
  104. NTRK fusions in thyroid cancer: Pathology and clinical aspects
  105. Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019
  106. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review)
  107. Case report: Maturity-Onset Diabetes of the Young (MODY12) caused by ABCC8 gene mutations
  108. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019
  109. Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
  110. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on Expression of FAM3 Members
  111. Advances in Understanding the Roles of Mesenchymal Stem Cells in Lung Cancer
  112. Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells
  113. Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice
  114. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
  115. Glutaminolysis and CD4+ T-cell metabolism in autoimmunity: From pathogenesis to therapy prospects
  116. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
  117. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
  118. COL1A1: A novel oncogenic gene and therapeutic target in malignancies
  119. The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus
  120. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
  121. Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy
  122. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
  123. Utilizing Network Pharmacology and Molecular Docking Integrated Surface Plasmon Resonance Technology to Investigate the Potential Targets and Mechanisms of Tripterygium wilfordii against Pulmonary Artery Hypertension
  124. Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report
  125. Doctor of Public Health-Crisis Management and COVID-19 Prevention and Control: A Case Study in China
  126. Online Education Plight and Countermeasures for MBBS in Chinese Regional Medical Schools Based on the OBE Concept During COVID-19 Pandemic
  127. Editorial: The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease
  128. Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway
  129. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related lncRNAs in Lung Adenocarcinoma
  130. Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients
  131. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
  132. A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis
  133. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  134. Identification of tRNA-derived Fragments and Their Potential Roles in Atherosclerosis
  135. Comprehensive overview of human serum albumin glycation in diabetes mellitus
  136. DL‑3‑n‑butylphthalide protects H9c2 cardiomyoblasts from ischemia/reperfusion injury by regulating HSP70 expression via PI3K/AKT pathway activation
  137. The analgesic efficacy of extracorporeal shock wave combined with percutaneous vertebroplasty in the treatment of osteoporotic thoracolumbar compression fractures in postmenopausal women
  138. Growth differentiation factor 11: a “rejuvenation factor” involved in regulation of age-related diseases?
  139. How to recognize and respond to viral re-positivity and disease relapse in patients with COVID-19
  140. Relationship between serum Dickkopf-1 and albuminuria in patients with type 2 diabetes
  141. Attaching clinical significance to COVID-19-associated diarrhea
  142. Identification of Potential Indicators for Survival in Patients With Thyroid Cancer Based on Mrna Expression Levels of Family With Sequence Similarity 3 Members
  143. Liraglutide improves obesity‐induced renal injury by alleviating uncoupling of the glomerular VEGF–NO axis in obese mice
  144. Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China
  145. Bioinformatic and biochemical findings disclosed anti-hepatic steatosis mechanism of calycosin
  146. SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion
  147. Novel insight into perirenal adipose tissue: A neglected adipose depot linking cardiovascular and chronic kidney disease
  148. Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis
  149. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
  150. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
  151. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
  152. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on mRNA Expression Levels of Family with Sequence Similarity 3 Members
  153. Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
  154. A Meta-Analysis of Pregnancy Outcomes with Levothyroxine Treatment in Euthyroid Women with Thyroid Autoimmunity
  155. AMPK: a balancer of the renin–angiotensin system
  156. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
  157. AMPK: a therapeutic target of heart failure—not only metabolism regulation
  158. Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics
  159. Calycosin directly improves perivascular adipose tissue dysfunction by upregulating the adiponectin/AMPK/eNOS pathway in obese mice
  160. C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese mice
  161. Irisin Improves Endothelial Dysfunction through Perivascular Adipose Tissue
  162. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice
  163. Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway
  164. Renal protective effects of induction of haem oxygenase-1 combined with increased adiponectin on the glomerular vascular endothelial growth factor-nitric oxide axis in obese rats
  165. Induction of Haemeoxygenase-1 Directly Improves Endothelial Function in Isolated Aortas from Obese Rats through the Ampk-Pi3k/Akt-Enos Pathway
  166. Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta
  167. The relationship between circulating irisin levels and endothelial function in lean and obese subjects
  168. Protective effects of adiponectin on uncoupling of glomerular VEGF–NO axis in early streptozotocin-induced type 2 diabetic rats
  169. Perirenal fat associated with microalbuminuria in obese rats
  170. Effect of high free fatty acids on the anti-contractile response of perivascular adipose tissue in rat aorta
  171. High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats
  172. Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients
  173. The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes in vivo and in vitro
  174. Serum Fetuin-A Levels Related with Microalbuminuria in Diet-Induced Obese Rats
  175. Time–Action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers
  176. Correlation of ultrasonographic measurement of intrarenal arterial resistance index with microalbuminuria in nonhypertensive, nondiabetic obese patients
  177. Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats
  178. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways
  179. High free fatty acids level related with cardiac dysfunction in obese rats
  180. Effect of Aspirin on the Expression of Hepatocyte NF-κB and Serum TNF-α in Streptozotocin-Induced Type 2 Diabetic Rats
  181. Effect of polysaccharides of theEuphoria longan(Lour.) Steud on inflammatory response induced by focal cerebral ischemia/reperfusion injury in rats